Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa
November 20, 2023 at 08:30 am EST
Share
Dyadic International, Inc. applauded the signing of an agreement between Dyadic?s African licensee, Rubic One Health and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic?s C1 protein production platform in South Africa for the entire continent. In April 2023, Dyadic expanded its licensing agreement with Rubic, whose mission is to develop African-based solutions for the discovery, development, evaluation and manufacture of high-quality, cost-effective human and animal vaccines and therapeutic proteins using Dyadic?s C1 expression platform for distribution primarily to the African market. The quest to produce affordable vaccines suited to humans and animals in Africa has taken a step closer to realization with the signing of the agreement between Rubic and Afreximaxbank.
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.